• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Amylyx Pharmaceuticals (AMLX) Is Down 10.1% After Strong Phase 3 Avexitide Data And $500M Equity Raise – Has The Bull Case Changed?

    Simply Wall St·08/29/2026 21:30:07
    语音播报
    • Earlier in August 2026, Amylyx Pharmaceuticals completed a US$500.20 million follow-on common stock offering after reporting that its Phase 3 LUCIDITY trial of avexitide for post-bariatric hypoglycemia met all primary and secondary endpoints with a strong safety profile.
    • The results highlight avexitide as a potential first-in-class GLP-1 receptor antagonist for a condition with no FDA-approved therapies, and Amylyx now plans to file a New Drug Application with the FDA by the end of 2026.
    • Next, we’ll examine how these successful Phase 3 avexitide results could reshape Amylyx’s previously risk-heavy investment narrative around its first commercial asset.

    Find 44 companies with promising cash flow potential yet trading below their fair value.

    Amylyx Pharmaceuticals Investment Narrative Recap

    To own Amylyx today, you need to believe avexitide can become an approved treatment for post bariatric hypoglycemia and support a broader rare disease platform. The strong Phase 3 LUCIDITY data directly addresses the prior trial risk and sets up the planned FDA filing as the key near term catalyst, while the biggest ongoing risk shifts toward execution on commercialization and reimbursement, given the company is still loss making and reliant on investor capital.

    Among the recent announcements, the completion of the US$500.20 million follow on common stock offering stands out in this context. Coming right after the positive LUCIDITY readout, it materially extends Amylyx’s cash resources for the NDA process, ongoing PBH programs and early neurodegeneration work, while also adding to an already growing share count. For current and prospective shareholders, that mix of funding strength and dilution sits at the heart of how attractive the avexitide story feels.

    Yet, even with encouraging LUCIDITY data in hand, the possibility that future capital needs could further dilute existing holders is something investors should be aware of...

    Read the full narrative on Amylyx Pharmaceuticals (it's free!)

    Amylyx Pharmaceuticals' narrative projects $168.0 million revenue and $36.4 million earnings by 2029. This implies an earnings increase of about $186 million from -$150.1 million today.

    Uncover how Amylyx Pharmaceuticals' forecasts yield a $25.56 fair value, a 26% downside to its current price.

    Exploring Other Perspectives

    AMLX 1-Year Stock Price Chart
    AMLX 1-Year Stock Price Chart

    Before this news, the most optimistic analysts were already modeling US$516.1 million of revenue and US$101.4 million of earnings by 2029, which shows just how far views can stretch and why it is worth comparing those bullish expectations with more cautious takes on avexitide’s approval, pricing and real world PBH uptake.

    Explore 2 other fair value estimates on Amylyx Pharmaceuticals - why the stock might be worth over 5x more than the current price!

    Decide For Yourself

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Curious About Other Options?

    Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.